Implementing a robust adverse event of special interest surveillance for novel oral polio vaccine type 2 rollout, Nigeria, March-July 2021

Environmental Surveillance and Vaccine Derived Polio Virus type 2 Isolation, Gombe State, Nigeria.

ObjectiveTo evaluate Vaccine Derived Polio Virus 2 isolation rate from Environmental Surveillance an

Circulating Vaccine‐Derived Poliovirus Type 2 (cVDPV2) Outbreak Response With Novel Oral Poliovirus Vaccine Type 2 (nOPV2), Sierra Leone's Experience

ABSTRACT Background In March 2024, a circulating vaccine‐derived poliovirus type 2 (cVDPV2) was i

Emergence of vaccine-derived strains from the novel oral polio vaccine in Central African Republic

BackgroundVaccine-derived polioviruses (VDPVs) pose a major challenge to the eradicat

Safety Surveillance During the Introduction of Novel Oral Poliovirus Vaccine Type 2 (nOPV2) in the Central African Republic: Findings from Passive AEFI and Active AESI Surveillance

Abstract Background Passive surveillance of adverse events following immunization

Exploring public perceptions of vaccine-derived poliovirus and a novel oral polio vaccine in the Democratic Republic of the Congo, Kenya, and Nigeria

Assessment of adverse events following vaccination with AstraZeneca Coronavirus Disease 2019 vaccine in Greater Kampala, Uganda, March-April 2021

Abstract Background Tracking of adverse events following vaccination is important for eva